DelveInsight has launched a new report on “Herpes Simplex Market Insights, Epidemiology, and Market Forecast- 2030”.
DelveInsight’s “Herpes Simplex – Market Insights, Epidemiology, and Market Forecast-2030“ report delivers an in-depth understanding of the Herpes Simplex, historical and forecasted epidemiology as well as the Herpes Simplex market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the Facts:
1. Around 3.7 billion people under the age of 50 (67%) with Herpes Simplex Virus-1 infection worldwide and around 417 million people aged 15-49 (11%) globally were affected with Herpes Simplex Virus -2 infection. 2. Approximately 776,000 people in the United States develop new Herpes Infections.
3. Most people are first exposed to HSV between 1 and 5 years of age.
4. It is more common among the women than in men.
Key benefits:
1. Herpes Simplex Virus market report covers a descriptive overview and comprehensive insight of the Herpes Simplex Virus epidemiology and Herpes Simplex Virus market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.) 2. Herpes Simplex Virus market report provides insights into current and emerging therapies. 3. Herpes Simplex Virus market report provides a global historical and forecasted market covering drug outreach in 7MM. 4. Herpes Simplex Virus market report offers an edge that will help in developing business strategies by understanding trends shaping and leading the Herpes Simplex Virus market.
Request for Free Sample Report: https://www.delveinsight.com/sample-request/herpes-simplex-market
The Herpes Simplex Virus, also known as HSV, is an infection which leads to small, painful, fluid-filled blisters on the skin, mouth, lips, eyes or genitals. This infection is categorized into two types: Herpes Simplex Virus Type-1 (HSV-1) and Herpes Simplex Virus Type-2 (HSV-2).
HSV-1 (Oral Herpes) is a highly contagious and common infection that is mainly transmitted by oral contact in or around the mouth, causing cold sores/Herpes Labialis as well as Genital Herpes in some cases. On the other hand, HSV-2 (Genital Herpes) is transmitted sexually (genital-to-genital, oral-to-genital, or genital-to-oral) and perinatally (mother to child). Both HSV-1 and HSV-2 infections are lifelong.
Already available drugs have provided therapeutic support to the high patient pool but their limited dose toxicity, interference with the normal metabolism of the body and ineffectiveness against drug-resistant cases which when applied topically may cause serious side effects. So, all these factors create a need for novel therapies with a different mechanism of action and molecular targets in a way that could be able to treat even resistant infections and prevent their recurrence. Deep sequencing techniques have led to a new appreciation of the genetic diversity of herpes virus genomes within an infected individual. Combination therapy for the management of HIV infections has been shown to be remarkably potent. It can suppress virus replication to undetectable levels and minimize the development of resistance.
Novel agents with favourable profiles with respect to their spectrum of antiviral activity, efficacy, oral bioavailability, pharmacokinetics, and toxicity could contribute greatly to the available Herpes Simplex Virus therapeutic options.
The rising number of patients with Herpes Simplex Virus infections, increasing awareness, and increasing research and development activities are some of the factors which are expected to contribute towards the Herpes Simplex Virus market growth during the forecast period (2017-2030).
The launch of the emerging therapies is expected to significantly impact Herpes Simplex Virus treatment scenario in the upcoming years: –
Drugs covered
1. Pritelivir 2. BTL-TML-HSV 3. VCL-HB01 4. Gen-003 and many others
The key players in Herpes Simplex Virus market are:
1. Vical 2. Genocea Biosciences 3. AiCuris 4. Beech Tree Labs 5. United BioPharma and many others
Table of contents: 1. Key Insights 2. Herpes Simplex Virus Market Overview at a Glance 3. Herpes Simplex Virus Disease Background and Overview 4. Herpes Simplex Virus Epidemiology and Patient Population 4.1. Key Findings 4.2. Population and Forecast Parameters 4.3. Herpes Simplex Virus Country Wise-Epidemiology 4.3.1.United States 4.3.2.Germany 4.3.3.France 4.3.4.Italy 4.3.5.Spain 4.3.6.United Kingdom 4.3.7.Japan 5. Herpes Simplex Virus Treatment Algorithm 6. Unmet needs 7. Herpes Simplex Virus Marketed drugs 8. Herpes Simplex Virus Emerging Therapies 9. Herpes Simplex Virus Infection Total Market Size in 7MM 10. Herpes Simplex Virus Market Size by Country 10.1. United States Market Analysis 10.2. Herpes Simplex Virus Infection EU5 Market Outlook 10.2.1. Germany 10.2.2. France 10.2.3. Italy 10.2.4. Spain 10.2.5. United Kingdom 10.3. Japan: Market Analysis 11. Herpes Simplex Virus Market Drivers 12. Herpes Simplex Virus Market Barriers 13. Appendix 14. DelveInsight Capabilities 15. Disclaimer
Request for Detailed TOC: https://www.delveinsight.com/sample-request/herpes-simplex-market
About DelveInsight DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/herpes-simplex-market